2021-10-25-深交所-嘉应制药_2021年第三季度报告_12页_304kb

报告摘要

Summary of Guangdong Jiaying Pharmaceutical Co. Ltd. Q3 2021 Report

Financial Highlights

Revenue: The company's revenue reached RMB 150.49 million in Q3 2021, showing a 2.20% year-over-year increase. Year-to-date revenue was RMB 402.77 million with a 13.30% growth.
Net Profit: Net profit was RMB 308,765.66 in Q3, a sharp decline of 88.31% compared to the same period last year. However, year-to-date net profit was RMB 4,494,564.57, experiencing a substantial increase of 1875.08% year-over-year.
Key Metrics: Operating cash flow was RMI 23.48 million, a 26.16% decrease; return on equity was 0.66%, up significantly from negative figures in Q3.

Governance and Management Issues

Board members Feng Biao and Xiao Yinan questioned the report's accuracy due to potential full loss on the company's investment in Kangci Medical, which may have resulted in significant asset losses. They also noted the lack of completion for required audits on previous board and management terms, limiting their ability to review past performance.
The report faced scrutiny from高管, who demanded third-party audits before endorsing the Q3 results, highlighting concerns about transparency and potential misstatements.

Operational Changes and Other Notes

Disputes over voting rights: Tiger Wealth Management attempted to revoke a delegation agreement with New Southern Medical, affecting control dynamics.
Impact on future plans: The company's non-public offering involving New Southern Medical remains uncertain due to these governance issues.
Financial fluctuations: Explanations for changes include increased prepayments, reduced debt interest costs, and adjustments for losses on investments held.

Shareholder Information

The top shareholders include major institutional and individual holders, with Tiger Wealth Management holding 11.27% of shares through a mix of loan agreements and voting constraints. Other key shareholders like Chen Yonghong and Huang Zhiyong control significant portions.

Overall Assessment

The report indicates a mix of financial challenges, such as declining profitability and heightened governance risks, alongside strategic uncertainties regarding key investments. The findings suggest potential liabilities that could affect future viability, and the company faces investor caution due to unresolved audit demands.

展开完整摘要